| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
20(R)-Protopanaxatriol is the ginsenosides Re, Rf, Rg1, Rg2, and Rh's natural aglycone[1].
|
|---|---|
| ln Vitro |
20(R)-Protopanaxatriol is the ginsenosides Re, Rf, Rg1, Rg2, and Rh's natural aglycone[1].
The review states that protopanaxadiol (PPD) and protopanaxatriol (PPT)-type saponins (which include 20(R)-Protopanaxatriol as a structural variant) have shown antidiabetic potential in in vitro and in vivo tests. Specific in vitro activity data for the 20(R)-isomer alone are not provided in the reviewed literature. [1] |
| ln Vivo |
The review mentions that PPD and PPT-type saponins (as a class, encompassing 20(R)-Protopanaxatriol) attenuated glucose tolerance and played a role in treating type 2 diabetes mellitus in animal models. They reduced fasting blood glucose (FBG) and regulated serum lipid markers (total cholesterol-TC, triglycerides-TG, low-density lipoprotein cholesterol-LDL-C) in a high-fat diet and streptozotocin-induced type 2 diabetes mellitus mouse model. [1]
PPD and PPT-type saponins also reduced the expression of inflammatory cytokines TNF-α and IL-6, contributing to the prevention of type 2 diabetes mellitus. [1] |
| Animal Protocol |
The review does not provide a detailed animal protocol (e.g., formulation, dosing regimen, route of administration) specifically for 20(R)-Protopanaxatriol. The mentioned effects for PPT-type saponins are based on studies using this class of compounds without specifying the isomeric form used. [1]
|
| References | |
| Additional Infomation |
It has been reported that ginseng contains 20(R)-protopanatriol, and there are related data reports. 20(R)-protopanatriol is one of the stereoisomers of the protopanatriol (PPT) aglycone skeleton in ginsenosides. PPT-type saponins are a major class of dammarane-type triterpenoid saponins in ginseng. [1] Like PPD-type saponins, PPT-type saponins (including 20(R)-protopanatriol) have attracted much attention for their antidiabetic effects, including improving glucose tolerance, regulating lipid metabolism, and exerting anti-inflammatory effects. [1] This review classifies various ginsenosides with the PPT skeleton into one class, and the data presented do not distinguish the specific contributions or unique characteristics of the 20(R)-isomer versus the 20(S)-isomer. [1]
|
| Molecular Formula |
C30H52O4
|
|---|---|
| Molecular Weight |
476.7315
|
| Exact Mass |
476.386
|
| CAS # |
1453-93-6
|
| PubChem CID |
9847853
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
590.0±50.0 °C at 760 mmHg
|
| Melting Point |
261-263 °C
|
| Flash Point |
240.1±24.7 °C
|
| Vapour Pressure |
0.0±3.8 mmHg at 25°C
|
| Index of Refraction |
1.541
|
| LogP |
5.89
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
34
|
| Complexity |
817
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
O([H])[C@]1([H])C([H])([H])[C@]2([H])[C@@]3(C([H])([H])[H])C([H])([H])C([H])([H])[C@@]([H])(C(C([H])([H])[H])(C([H])([H])[H])[C@]3([H])[C@]([H])(C([H])([H])[C@@]2(C([H])([H])[H])C2(C([H])([H])[H])C([H])([H])C([H])([H])[C@]([H])([C@@](C([H])([H])[H])(C([H])([H])C([H])([H])/C(/[H])=C(\C([H])([H])[H])/C([H])([H])[H])O[H])[C@]21[H])O[H])O[H]
|
| InChi Key |
SHCBCKBYTHZQGZ-DLHMIPLTSA-N
|
| InChi Code |
InChI=1S/C30H52O4/c1-18(2)10-9-13-30(8,34)19-11-15-28(6)24(19)20(31)16-22-27(5)14-12-23(33)26(3,4)25(27)21(32)17-29(22,28)7/h10,19-25,31-34H,9,11-17H2,1-8H3/t19-,20+,21-,22+,23-,24-,25-,27+,28+,29+,30+/m0/s1
|
| Chemical Name |
(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-17-[(2R)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,6,12-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 32 mg/mL (~67.12 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0976 mL | 10.4881 mL | 20.9762 mL | |
| 5 mM | 0.4195 mL | 2.0976 mL | 4.1952 mL | |
| 10 mM | 0.2098 mL | 1.0488 mL | 2.0976 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
